Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma

Chen, Hui; Sun, Lingyu; Zheng, Haixue; Zhang, Qi-fan; Jin, Xiaoming

doi:10.1097/pat.0b013e328353a24c

Cited by 52 publications

(53 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While a recent meta-analysis of 2,424 subjects including 1,280 HCC patients in 22 studies concluded that quantitative cfDNA may have a potential role for HCC diagnosis in combining with AFP with a sensitivity of 82% and specificity of 96% and AUC of 0.96, 46 additional studies have not replicated these initially promising results. [47][48][49] Overall, it appears that cfDNA concentration in serum or plasma reflects tumor burden and there were wide variations in the concentration of cfDNA even among healthy controls, suggesting that the level can vary depending on the assay platform. Indeed, there are various ways in which cfDNA "levels" have been reported and one must pay attention to the units of measurement, and that serial assessments should be done using the same platform to limit variability between assays.…”

Section: Quantitative Cfdnamentioning

confidence: 99%

Circulating Tumor DNA and Hepatocellular Carcinoma

2019

View full text Add to dashboard Cite

There is a clear and unmet need for biomarkers in hepatocellular carcinoma (HCC). Circulating cell free deoxyribonucleic acid (cfDNA) is a fragmented DNA subtype, found in the blood circulation. Circulating tumor DNA (ctDNA) is the fraction of total cfDNA, which originates from the primary tumor or metastases in patients with cancer. Earlier studies reported that quantitative measurement cfDNA has diagnostic and prognostic role for HCC. More recently, improvement in next-generation sequencing technology and better understanding of genetic or epigenetic alteration of HCC have allowed comprehensive analysis of mutational and methylation landscape of ctDNA. Hotspot mutation panels and methylation panels have both shown promising performance. None of these tests have yet been validated in longitudinal cohorts for preclinical detection of HCC. In this article, the authors discuss the currently available ctDNA detection technologies, their diagnostic and prognostic performance in HCC, and future research directions.

show abstract

Section: Quantitative Cfdnamentioning

confidence: 99%

Circulating Tumor DNA and Hepatocellular Carcinoma

2019

View full text Add to dashboard Cite

show abstract

“…Patients with cancer have a significantly elevated level of cfDNA integrity compared to healthy individuals and patients with benign diseases. 83,84 High integrity is explained by augmented levels of necrotic death in large tumors at advanced stages, and it is also associated with tumor aggressiveness. 76,83 Apart from apoptotic and necrotic cell death, other DNA release mechanisms have been described, including oncosis, pyroptosis, phagocytosis, active secretion, neutrophil extracellular trap release (NETosis), and excision repair.…”

Section: Introductionmentioning

confidence: 99%

“…83,84 High integrity is explained by augmented levels of necrotic death in large tumors at advanced stages, and it is also associated with tumor aggressiveness. 76,83 Apart from apoptotic and necrotic cell death, other DNA release mechanisms have been described, including oncosis, pyroptosis, phagocytosis, active secretion, neutrophil extracellular trap release (NETosis), and excision repair. 24,[85][86][87][88][89] In contrast to various forms of cell death, active secretion occurs in live, functional cells.…”

Section: Introductionmentioning

confidence: 99%

Life and death of circulating cell-free DNA

Kustanovich

Schwartz

Peretz

et al. 2019

Cancer Biology & Therapy

382

386

View full text Add to dashboard Cite

Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of biomarkers for minimally invasive serial monitoring of treatment responses in cancer management. We will review the current understanding of the origin of circulating cell-free DNA and different forms of DNA release (including various types of cell death and active secretion processes) and clearance routes. The dynamics of extracellular DNA in blood during therapy and the role of circulating DNA in pathophysiological processes (tumor-associated inflammation, NETosis, and pre-metastatic niche development) provide insights into the mechanisms that contribute to tumor development and metastases formation. Better knowledge of circulating tumor-specific cell-free DNA could facilitate the development of new therapeutic and diagnostic options for cancer management. ARTICLE HISTORY

show abstract

“…Several studies have shown that HCC patients have large amounts of cfDNA being these associated with the degree of malignancy (poorer prognosis) and size of the tumor size [77,78] . Huang et al [77] showed that plasma DNA detection was able to discriminate HCC from normal controls with 90.2% sensitivity and 90.3% specificity and AUC was 0.949 (95% CI) (measured by real-time quantitative PCR method).…”

Section: Cell-free Tumor Associated Dnamentioning

confidence: 99%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma

Cited by 52 publications

References 36 publications

Circulating Tumor DNA and Hepatocellular Carcinoma

Circulating Tumor DNA and Hepatocellular Carcinoma

Life and death of circulating cell-free DNA

Performance of different biomarkers for the management of hepatocellular carcinoma

Contact Info

Product

Resources

About